{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T05:40:38Z","timestamp":1697866838403},"reference-count":9,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2006,7,20]],"date-time":"2006-07-20T00:00:00Z","timestamp":1153353600000},"content-version":"vor","delay-in-days":8601,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Med. Pediatr. Oncol."],"published-print":{"date-parts":[[1983,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Because of an encouraging response rate in a pilot study of adriamycin, BCNU, and cyclophosphamide (ABC), the Southeastern Cancer Study Group conducted a phase II study of ABC in patients with melphalan\u2010resistant ovarian carcinoma. Of 36 evaluable patients, there were only 4 partial responses to therapy, for a partial response rate of 11%. Durations of response were 4 to 50 + weeks, and the overall median survival was 29 weeks. No complete responses were seen. Dose\u2010limiting toxicity was granulocytopenia. We conclude that ABC is generally ineffective in management of alkylator\u2010resistant ovarian adenocarcinoma.<\/jats:p>","DOI":"10.1002\/mpo.2950110302","type":"journal-article","created":{"date-parts":[[2007,2,20]],"date-time":"2007-02-20T15:44:11Z","timestamp":1171986251000},"page":"151-153","source":"Crossref","is-referenced-by-count":0,"title":["Adriamycin, BCNU, and cyclophosphamide in drug\u2010resistant adenocarcinoma of the ovary"],"prefix":"10.1002","volume":"11","author":[{"given":"Cary A.","family":"Presant","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfred","family":"Bartolucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,7,20]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"267","article-title":"Chemotherapy of ovarian cancer: Past and present","volume":"2","author":"Young RC","year":"1975","journal-title":"Semin Oncol"},{"key":"e_1_2_1_3_2","first-page":"307","article-title":"Phase II trial of cyclophosphamide, hexamethylmelamine, Adriamycin and cis\u2010dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinoma","volume":"63","author":"Kane R","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_4_2","first-page":"311","article-title":"The CHAD and HAD regimens in advanced ovarian cancer: Combination chemotherapy including cyclophosphamide, hexamethylmelamine, Adriamycin, and cis,\u2010dichlorodiammineplatinum(II)","volume":"63","author":"Vogl SE","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.241.18.1908"},{"key":"e_1_2_1_6_2","first-page":"149","article-title":"Cyclophosphamide, hexamethylmelamine, doxonibicin, and cisplatin (CHAD) as second\u2010line chemotherapy for ovarian adenocarcinoma","volume":"65","author":"Piver MS","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_7_2","first-page":"172","article-title":"Hexamethylmelamine, doxorubicin, and cyclophosphamide in advanced ovarian cancer resistant to previous chemotherapy","volume":"65","author":"Sessa C","year":"1981","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197602)37:2<620::AID-CNCR2820370203>3.0.CO;2-D"},{"key":"e_1_2_1_9_2","first-page":"301","article-title":"Combination chemotherapy for alkylator\u2010resistant ovarian carcinoma: A preliminary report of a Southwest Oncology Group trial","volume":"63","author":"Alberts DS","year":"1979","journal-title":"Cancer Treat Rep"},{"key":"e_1_2_1_10_2","first-page":"1539","article-title":"cis,\u2010Dichlorodiammineplatinum(II) for the treatment of advanced ovarian cancer","volume":"63","author":"Young RC","year":"1979","journal-title":"Cancer Treat Rep"}],"container-title":["Medical and Pediatric Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmpo.2950110302","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mpo.2950110302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:13:26Z","timestamp":1697771606000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/mpo.2950110302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1983,1]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1983,1]]}},"alternative-id":["10.1002\/mpo.2950110302"],"URL":"https:\/\/doi.org\/10.1002\/mpo.2950110302","archive":["Portico"],"relation":{},"ISSN":["0098-1532","1096-911X"],"issn-type":[{"value":"0098-1532","type":"print"},{"value":"1096-911X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1983,1]]}}}